Norethindrone

Nora-BE norethindrone 0.35 mg is a prescription progestin-only pill (POP) for pregnancy prevention. Selected norethindrone acetate 5 mg treats secondary amenorrhea, endometriosis and abnormal uterine bleeding due to hormonal imbalance after organic causes, such as fibroids or cancer, are excluded. Acetate is not approved as contraception or recommended for postmenopausal endometrial protection with estrogen.

The contraceptive tablet contains no estrogen and does not protect against HIV or other sexually transmitted infections. CDC POP recommendations address contraceptive dosing, not high-dose acetate therapy. This profile excludes estrogen combinations, menopausal combination therapy, norgestrel OTC pills and drospirenone-only pills; each has different instructions.

Nora-BE label prefers starting on the first menstrual day; another starting day requires backup for 48 hours. Professional counseling says 3 or more hours late requires backup; the patient leaflet uses more than 3 hours. Use the conservative backup threshold of 3 hours. For a late/missed pill: take one as soon as remembered, then resume the usual schedule and use backup for the next 48 hours. Two pills can fall on the same day. Vomiting soon after a pill requires 48-hour backup under the label. Do not create a placebo interval or stop merely for spotting.

CDC permits starting when reasonably certain pregnancy is absent: no backup within the first 5 menstrual days, otherwise 2 days. This differs from Nora-BE’s day-one instructions. CDC permits immediate postpartum initiation, with individualized breastfeeding and backup assessment, rather than the label’s later postpartum start. After vomiting within 3 hours, repeat the pill promptly and use backup through 2 days after illness resolves. Missed pills can require emergency contraception; CDC excludes ulipristal from this immediate POP-resumption advice. Use the current linked guide for switching and postpartum specifics.

No validated fixed renal adjustment is supplied for either selected product. Renal PK of high-dose acetate has not been studied; data from lower-dose combined pills in dialysis do not establish an acetate regimen. Nora-BE is contraindicated with acute liver disease or liver tumors; acetate with impaired liver function or liver disease. Observe acetate-associated fluid retention in renal/cardiac disease and individualize treatment rather than applying a percentage dose reduction.

Nora-BE: known/suspected pregnancy or breast cancer, undiagnosed genital bleeding, allergy, benign/malignant liver tumors or acute liver disease. Selected acetate: pregnancy, undiagnosed vaginal bleeding, known/suspected/history of breast cancer, active/history of DVT or PE, active/recent arterial thromboembolism (e.g. stroke or MI within the past year), impaired liver function/liver disease, hypersensitivity, or use as a diagnostic pregnancy test. Do not transfer acetate’s VTE contraindication to every contraceptive POP.

Neither selected current U.S. label has a boxed warning. Nora-BE contains smoking counseling; the estrogen-combination smoking-over-35 boxed warning should not be copied to this estrogen-free product. Acetate’s thromboembolic contraindications remain important.

Minipill: unpredictable spotting/bleeding or amenorrhea, headache, breast tenderness, nausea and dizziness; acne, hirsutism or weight change are less frequent. Acetate adds edema, depression/mood changes, insomnia, cholestatic jaundice, liver/lipid abnormalities, allergic reactions and reported thromboembolism. Postmarketing frequencies are not reliably quantified. The Nora-BE label reports no serious effects from accidental large ingestions; this is not a reason to ignore an exposure. Obtain Poison Help/clinical advice (U.S. 1-800-222-1222); the selected acetate label provides no detailed overdose regimen.

The need for interaction review depends on the specific drug and enzyme effects; do not treat all antibiotics as equivalent to rifampin. Review the selected product and contraceptive plan when any new medicine or supplement is added.

Both selected products are contraindicated in known/suspected pregnancy; stop the contraceptive pill and contact the clinician if pregnancy is suspected. POP exposure studies do not establish a major fetal-development signal, but treatment is unnecessary in pregnancy. Acetate labeling warns of fetal harm and reported genital abnormalities with early progestational exposure. Small progestin amounts enter milk; Nora-BE reports rare reduced milk production/jaundice. Acetate professional labeling advises nursing caution, while its patient leaflet says not to use while breastfeeding; follow the stricter patient instruction pending clinician review of the exact product. Do not assume high-dose acetate has the contraceptive POP’s lactation evidence.

Nora-BE is for reproductive-age patients after menarche; effectiveness/safety in postpubertal adolescents younger than 16 is expected to match older users. It is not indicated before menarche. Fertility generally returns rapidly after stopping. Selected acetate is not indicated in children and is not recommended as postmenopausal estrogen-associated endometrial protection. Neither label supplies a routine geriatric dose.

CDC classifies contraceptive POP use with smoking or obesity as category 1 (no restriction); current breast cancer is category 4 (unacceptable risk), and past breast cancer without disease for 5 years is category 3. These contraceptive categories do not authorize high-dose acetate or erase an individual product’s contraindications. Use the full current eligibility tables for comorbidity decisions.

No fixed renal adjustment is established. Hepatic contraindications differ by selected product and require clinical assessment. With acetate, monitor fluid retention, diabetes, dyslipidemia, severe recurrent depression and cardiovascular/VTE risk; with the POP, assess absorption, bleeding and interacting medicines rather than adopting estrogen-combination restrictions automatically.

Norethindrone POP thickens cervical mucus, modifies the endometrium and tubal transport, and suppresses ovulation in approximately half of users; consistent timing is important. Acetate is rapidly converted to norethindrone and produces progestational endometrial changes in estrogen-primed tissue. Its different dose/regimen supports the labeled gynecologic treatment roles.

Norethindrone 0.35 mg

Peak ~1–2 hours; absolute bioavailability ~65%; elimination half-life ~8 hours.

Selected acetate 5 mg

Rapid deacetylation; norethindrone peaks around 2 hours and mean half-life around 9 hours in the label’s single-dose study.

Distribution / metabolism

Norethindrone is largely SHBG/albumin bound and undergoes hepatic reduction/conjugation.

Elimination / food

Metabolites leave in urine/feces; neither selected label establishes a food-effect dosing adjustment. PK does not justify mg-for-mg interchange.

Confirm exact indication, pregnancy status, bleeding evaluation, liver/breast history, interacting drugs and relevant comorbidities. For the minipill, review daily timing, missed pills, GI illness, pregnancy symptoms and bleeding; assess diabetes control when applicable. For acetate, follow bleeding/endometriosis response, mood, edema, BP/cardiovascular risk and lipids/glucose in at-risk patients. Reassess unexpected bleeding or liver/visual/thrombotic symptoms promptly.

Know whether the prescription is 0.35 mg norethindrone or 5 mg acetate. For the minipill, choose one daily time, arrange the next pack before finishing and use the documented backup plan after a missed/late pill. Contact the clinician for suspected pregnancy, severe abdominal pain or persistent abnormal bleeding. Condoms reduce STI risk; these pills do not. Discuss pregnancy intentions, breastfeeding, smoking and all drugs/supplements. Acetate course changes and treatment interruptions require an indication-specific plan.

Nora-BE 0.35 mg norethindrone: white flat round tablet marked TV / N62; 28 active tablets per blister card. Teva example NDC 0480-3475-16 is a carton of six cards. Appearance is product-specific and is not a safe substitute for checking the labeled ingredient/strength.

Store both selected tablets at 20–25°C. Keep in labeled packaging away from children and check expiry. Preserve the minipill’s daily pack sequence and uninterrupted next-pack supply; do not infer a placebo week from combined contraceptive packs.